


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+1.81%
-7.88%
+1.59%
+17.89%
ABBV
AbbVie
$219.25
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Investors confidence is positive
Chart
$230.69 (-4.96%)
$201.47 (+8.83%)
$190.86 (+14.87%)
$166.57 (+31.63%)
ABBV has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

ABBV overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Earnings decline YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
ABBV Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ABBV Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayPFE
24.44
-0.23%
NVS
126.38
-0.15%
SNY
49.66
+0.34%
LLY
924.37
-1.39%
MRK
86.05
+0.58%
What is ABBV current stock price?
What are ABBV stock strengths?
What risks are associated with ABBV stock?
When is ABBV next earnings report?
What is ABBV market cap and volume?
What is ABBV's current Stock IQ?
Should I buy ABBV stock right now?
Is ABBV a Strong Buy right now?
What does a 'Strong Buy' rating mean for ABBV?
What does a 'Strong Sell' rating mean for ABBV?
What factors influence ABBV's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.81%
-7.88%
+1.59%
+17.89%
ABBV
AbbVie
Current Price
$219.25
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

Investors confidence is positive
Linked to ABBV
PFE
24.44
-0.23%
NVS
126.38
-0.15%
SNY
49.66
+0.34%
LLY
924.37
-1.39%
MRK
86.05
+0.58%

Chart
$230.69 (-4.96%)
$201.47 (+8.83%)
$190.86 (+14.87%)
$166.57 (+31.63%)
ABBV Analysts Opinion
ABBV Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Earnings decline YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
ABBV Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ABBV Street view is extremely bullish and have positive views on the near-term outlook
ABBV has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

Average key support and resistance price levels.
ABBV Latest Analysis
3 Dividend Stocks Down 11% 29% and 41% to Buy in November. Key PointsAbbVie continues to enjoy strong growth from its new blockbuster drugs Rinvoq and Skyrizi.
Thu Nov 6, 2025
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today. AbbVie (NYSE:) has outperformed the market over the past 5 years by 3.1% on an annualized basis producing an average annual return of 17.03%. Currently AbbVie has a market capitalization of $383.45 billion.
Wed Nov 5, 2025
Choroidal Neovascularization Market to Witness Accelerated Growth Throughout the Forecast Period (2025–2034) Due to Advancement in Anti-VEGF Therapies | DelveInsight. Choroidal Neovascularization Market to Witness Accelerated Growth Throughout the Forecast Period (2025–2034) Due to Advancement in Anti-VEGF Therapies |. DelveInsightThe choroidal neovascularization therapeutics market is expected to further increase due to major drivers including the rising prevalence of the population technol
Wed Nov 5, 2025
Citigroup Maintains AbbVie (ABBV) Neutral Recommendation. Fintel reports that on November 3 2025 Citigroup maintained coverage of AbbVie (NYSE:ABBV) with a Neutral recommendation. Analyst Price Forecast Suggests 14.37% Upside
Tue Nov 4, 2025
JP Morgan Maintains AbbVie (ABBV) Overweight Recommendation. Fintel reports that on November 3 2025 JP Morgan maintained coverage of AbbVie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 14.37% Upside
Tue Nov 4, 2025
My Favorite Dividend King to Buy in November. Key PointsAbbVie has increased its dividend for 53 consecutive years and more than quadrupled its dividend since 2013.
Mon Nov 3, 2025
Analyst on AbbVie (ABBV): Stay Long. We recently published 10 Stocks Everyones Discussing Amid Latest Earnings Season. AbbVie Inc. (NYSE:ABBV) is one of the stocks everyone’.s discussing. Jason Snipe the Founder and Chief Investment Officer of Odyssey Capital Advisors recommended investors to stay long AbbVie Inc (NYSE:ABBV) during a recent program on CNBC. ABBV shares are up 21% so far this [….]
Mon Nov 3, 2025
AbbVie raises 2025 EPS guidance and signals strong pipeline milestones into 2026.
Fri Oct 31, 2025
AbbVie Q3 Earnings & Sales Beat 2025 EPS Outlook Raised. ABBV tops Q3 earnings and revenue estimates driven by Rinvoq and Skyrizi gains and lifts its 2025 EPS outlook.
Fri Oct 31, 2025
AbbVie Q3 Profit Decreases But Beats Estimates . (RTTNews) - AbbVie (ABBV) revealed a profit for third quarter that Decreased from last year but beat the Street estimates.
Fri Oct 31, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ABBV Stock trends
ABBV Stock performance
ABBV Stock analysis
ABBV investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.